Novavax Inc. said Friday that its experimental COVID-19 booster is being tested in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. This study is evaluating Novavax’s protein-based booster candidate in people who have already received the primary series of shots developed by BioNTech SE and Pfizer Inc. , Johnson & Johnson , or Moderna Inc. . (Novavax’s COVID-19 vaccine has not been authorized in the U.S.; it is currently being reviewed by the Food and Drug Administration.) The study is enrolling 1,130 adults; approximately 180 of them will receive the Novavax shot as a booster. Novavax’s stock has declined 43.0% so far this year, while the S&P 500 is down 5.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
0
0
